Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma

Background To overcome challenges with traditional response assessment in anti-angiogenic agents, the current study uses T1 subtraction maps to quantify volumetric radiographic response in monotherapy with cabozantinib, an orally bioavailable tyrosine kinase inhibitor with activity against vascular endothelial growth factor receptor 2 (VEGFR2), hepatocyte growth factor receptor (MET), and AXL, in an open-label, phase II trial in patients with recurrent glioblastoma (GBM) (NCT00704288). Methods A total of 108 patients with adequate imaging data and confirmed recurrent GBM were included in this retrospective study from a phase II multicenter trial of cabozantinib monotherapy (XL184-201) at either 100 mg (N = 87) or 140 mg (N = 21) per day. Contrast enhanced T1-weighted digital subtraction maps were used to define volume of contrast-enhancing tumor at baseline and subsequent follow-up time points. Volumetric radiographic response (>65% reduction in contrast-enhancing tumor volume from pretreatment baseline tumor volume sustained for more than 4 wk) was tested as an independent predictor of overall survival (OS). Results Volumetric response rate for all therapeutic doses was 38.9% (41.4% and 28.6% for 100 mg and 140 mg doses, respectively). A log-linear association between baseline tumor volume and OS (P = 0.0006) and a linear correlation between initial change in tumor volume and OS (P = 0.0256) were observed. A significant difference in OS was observed between responders (median OS = 20.6 mo) and nonresponders (median OS = 8.0 mo) (hazard ratio [HR] = 0.3050, P < 0.0001). Multivariable analyses showed that continuous measures of baseline tumor volume (HR = 1.0233, P < 0.0001) and volumetric response (HR = 0.2240, P < 0.0001) were independent predictors of OS. Conclusions T1 subtraction maps provide value in determining response in recurrent GBM treated with cabozantinib and correlated with survival benefit.

[1]  P. Wen,et al.  Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study , 2019, Neuro-oncology.

[2]  P. Wen,et al.  A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE) , 2019, Neuro-oncology.

[3]  Yonehiro Kanemura,et al.  Radiomics and MGMT promoter methylation for prognostication of newly diagnosed glioblastoma , 2019, Scientific Reports.

[4]  P. Wen,et al.  Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma , 2018, Nature Medicine.

[5]  Martin Klein,et al.  Lomustine and Bevacizumab in Progressive Glioblastoma , 2017, The New England journal of medicine.

[6]  T. Mikkelsen,et al.  Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy , 2017, Neuro-oncology.

[7]  T. Mikkelsen,et al.  Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy , 2017, Neuro-oncology.

[8]  R. Vernhout,et al.  Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab—a report from the BELOB trial , 2017, Neuro-oncology.

[9]  P. Tamboli,et al.  Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma , 2016, Oncogene.

[10]  A. Ullrich,et al.  Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo , 2016, Oncotarget.

[11]  P. Kantoff,et al.  Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[12]  R. Vernhout,et al.  Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. , 2014, The Lancet. Oncology.

[13]  Benjamin M Ellingson,et al.  Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. , 2014, Radiology.

[14]  M. Kreissl,et al.  Cabozantinib in progressive medullary thyroid cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. A. van der Laak,et al.  Effects of Dual Targeting of Tumor Cells and Stroma in Human Glioblastoma Xenografts with a Tyrosine Kinase Inhibitor against c-MET and VEGFR2 , 2013, PloS one.

[16]  David C. Smith,et al.  Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  T. Tokuyasu,et al.  Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance , 2013, Clinical Cancer Research.

[18]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[19]  Barbara Sennino,et al.  Controlling escape from angiogenesis inhibitors , 2012, Nature Reviews Cancer.

[20]  D. Cheresh,et al.  VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. , 2012, Cancer cell.

[21]  Yongchang Shi,et al.  Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth , 2011, Molecular Cancer Therapeutics.

[22]  M. Ratain,et al.  Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  W. You,et al.  VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. , 2011, Cancer research.

[24]  R. McLendon,et al.  A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[25]  R. Weimer,et al.  An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies , 2010, Oncogene.

[26]  A. Thorburn,et al.  Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved Chemosensitivity , 2010, Molecular Cancer Therapeutics.

[27]  Bjørn Tore Gjertsen,et al.  Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival , 2009, Proceedings of the National Academy of Sciences.

[28]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[30]  M. Chamberlain.  BEVACIZUMAB FOR RECURRENT MALIGNANT GLIOMAS: EFFICACY, TOXICITY, AND PATTERNS OF RECURRENCE , 2009, Neurology.

[31]  John A Butman,et al.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  W. Yung,et al.  Bevacizumab and Irinotecan in the Treatment of Recurrent Malignant Gliomas , 2008, Cancer journal.

[33]  D. Blumenthal,et al.  Treatment with bevacizumab and irinotecan for recurrent high‐grade glial tumors , 2008, Cancer.

[34]  D. Peereboom,et al.  Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety , 2008, Journal of Neuro-Oncology.

[35]  A. Ullrich,et al.  Axl and Growth Arrest–Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme , 2008, Clinical Cancer Research.

[36]  John Sampson,et al.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Darell D. Bigner,et al.  Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.

[38]  T. Cloughesy,et al.  MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy , 2006, Neurology.

[39]  D. Gillespie,et al.  Inhibition of hypoxia inducible factor-1α (HIF-1α) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas , 2006, Journal of Neuro-Oncology.

[40]  M. Essig,et al.  Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Laterra,et al.  Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. , 2005, Neuro-oncology.

[42]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[43]  R. Ondarza,et al.  Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma , 2002, Cancer.

[44]  R. McLendon,et al.  Irinotecan therapy in adults with recurrent or progressive malignant glioma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Christian,et al.  Measuring response in solid tumors: unidimensional versus bidimensional measurement. , 1999, Journal of the National Cancer Institute.

[46]  M. Mehta,et al.  Dimension in defining tumor response. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[48]  P. Wen,et al.  Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials , 2017, Neuro-oncology.

[49]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. , 2013, Neuro-oncology.

[50]  Do-Hyun Nam,et al.  Prognostic significance of c‐Met expression in glioblastomas , 2009, Cancer.

[51]  M. Mrugala,et al.  Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. , 2009, Neurology.

[52]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[53]  Tracy T Batchelor,et al.  Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. , 2006, Neuro-oncology.

[54]  Susan M. Chang,et al.  A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. , 2006, Neuro-oncology.